Shanmugasundaram Ganapathy-Kannia

List of Publications by Year
in descending order

56 papers	2,154 citations	377584 21 h-index	274796 44 g-index
63 all docs	63 docs citations	63 times ranked	3836 citing authors

#	ARTICLE	IF	CITATIONS
1	Augmented Liver Uptake of the Membrane Voltage Sensor Tetraphenylphosphonium Distinguishes Early Fibrosis in a Mouse Model. Frontiers in Physiology, 2021, 12, 676722.	1.3	0
2	Rac1 repression reverses chemoresistance by targeting tumor metabolism. Cancer Biology and Therapy, 2020, 21, 888-890.	1.5	11
3	PFKP phenotype in lung cancer: prognostic potential and beyond. Molecular Biology Reports, 2020, 47, 8271-8272.	1.0	7
4	pI Determination of Native Proteins In Biological Samples. Current Protocols in Protein Science, 2019, 96, e85.	2.8	1
5	Elevated mitochondrial activity distinguishes fibrogenic hepatic stellate cells and sensitizes for selective inhibition by mitotropic doxorubicin. Journal of Cellular and Molecular Medicine, 2018, 22, 2210-2219.	1.6	27
6	Turning cancer's metabolic plasticity into fragility- an evolving paradigm. Cancer Biology and Therapy, 2018, 19, 763-765.	1.5	2
7	Evolution of GAPDH as a druggable target of tumor glycolysis?. Expert Opinion on Therapeutic Targets, 2018, 22, 295-298.	1.5	29
8	Molecular intricacies of aerobic glycolysis in cancer: current insights into the classic metabolic phenotype. Critical Reviews in Biochemistry and Molecular Biology, 2018, 53, 667-682.	2.3	140
9	GAPDH with NAD+-binding site mutation competitively inhibits the wild-type and affects glucose metabolism in cancer. Biochimica Et Biophysica Acta - General Subjects, 2018, 1862, 2555-2563.	1.1	10
10	Linking tumor glycolysis and immune evasion in cancer: Emerging concepts and therapeutic opportunities. Biochimica Et Biophysica Acta: Reviews on Cancer, 2017, 1868, 212-220.	3.3	70
11	Preclinical Benefit of Hypoxia-Activated Intra-arterial Therapy with Evofosfamide in Liver Cancer. Clinical Cancer Research, 2017, 23, 536-548.	3.2	27
12	Analysis of GAPDH Enzyme Activity: A Quantitative and Qualitative Approach. , 2017, , 5-15.		0
13	Purification of GAPDH. , 2017, , 99-104.		0
14	Is There an Opportunity for Current Chemotherapeutics to Up-regulate MIC-A/B Ligands?. Frontiers in Pharmacology, 2017, 8, 732.	1.6	2
15	Taming Tumor Glycolysis and Potential Implications for Immunotherapy. Frontiers in Oncology, 2017, 7, 36.	1.3	26
16	Editorial: Cancer Metabolism: Molecular Targeting and Implications for Therapy. Frontiers in Oncology, 2017, 7, 232.	1.3	4
17	Analysis of GAPDH and Protein Interaction. , 2017, , 39-53.		2
18	Analysis of GAPDH Posttranslational Modifications. , 2017, , 85-94.		1

#	Article	IF	Citations
19	Analysis of GAPDH and Nucleic Acid Interaction. , 2017, , 55-65.		0
20	Analysis of Subcellular and Extracellular GAPDH. , 2017, , 67-83.		0
21	Analysis of GAPDH â€“ Native Protein. , 2017, , 17-26.		0
22	Deregulation of energy metabolism promotes antifibrotic effects in human hepatic stellate cells and prevents liver fibrosis in a mouse model. Biochemical and Biophysical Research Communications, 2016, 469, 463-469.	1.0	27
23	Targeting tumor glycolysis by a mitotropic agent. Expert Opinion on Therapeutic Targets, 2016, 20, 1-5.	1.5	9
24	Targeting Glycolytic Adaptations of Cancer Cells: From Molecular Mechanisms to Therapeutic Opportunities. , 2015, , 331-344.		2
25	Occurrence of a Multimeric High-Molecular-Weight Glyceraldehyde-3-phosphate Dehydrogenase in Human Serum. Journal of Proteome Research, 2015, 14, 1645-1656.	1.8	18
26	Metabolic perturbation sensitizes human breast cancer to NK cell-mediated cytotoxicity by increasing the expression of MHC class I chain-related A/B. OncoImmunology, 2015, 4, e991228.	2.1	15
27	Abstract 5271: Hepatic hypoxia-activated intra-arterial therapy: effect of selective targeting of hypoxia in a rabbit liver tumor model. , 2015, , .		0
28	Tumor cells and memory T cells converge at glycolysis. Cancer Biology and Therapy, 2014, 15, 483-485.	1.5	4
29	Is the pathway of energy metabolism modified in advanced cirrhosis?. Journal of Hepatology, 2014, 61, 452.	1.8	4
30	Systemic Delivery of Microencapsulated 3-Bromopyruvate for the Therapy of Pancreatic Cancer. Clinical Cancer Research, 2014, 20, 6406-6417.	3.2	47
31	Reversal of Anchorage-Independent Multicellular Spheroid into a Monolayer Mimics a Metastatic Model. Scientific Reports, 2014, 4, 6816.	1.6	27
32	Systemic administration of 3-bromopyruvate reveals its interaction with serum proteins in a rat model. BMC Research Notes, 2013, 6, 277.	0.6	19
33	Ultrasound-guided direct delivery of 3-bromopyruvate blocks tumor progression in an orthotopic mouse model of human pancreatic cancer. Targeted Oncology, 2013, 8, 145-151.	1.7	25
34	Tumor glycolysis as a target for cancer therapy: progress and prospects. Molecular Cancer, 2013, 12, 152.	7.9	837
35	Statins impair glucose uptake in tumor cells. Cancer Biology and Therapy, 2013, 14, 92-94.	1.5	2
36	Anticancer efficacy of the metabolic blocker 3-bromopyruvate: specific molecular targeting. Anticancer Research, 2013, 33, 13-20.	0.5	55

#	Article	IF	Citations
37	Human Hepatocellular Carcinoma in a Mouse Model: Assessment of Tumor Response to Percutaneous Ablation by Using Glyceraldehyde-3-Phosphate Dehydrogenase Antagonists. Radiology, 2012, 262, 834-845.	3.6	44
38	Spontaneous Tumor Regression in a Syngeneic Rat Model of Liver Cancer: Implications for Survival Studies. Journal of Vascular and Interventional Radiology, 2012, 23, 1685-1691.	0.2	26
39	Glyceraldehyde-3-Phosphate Dehydrogenase: A Promising Target for Molecular Therapy in Hepatocellular Carcinoma. Oncotarget, 2012, 3, 940-953.	0.8	79
40	Assessment of Tumoricidal Efficacy and Response to Treatment with¹⁸F-FDG PET/CT After Intraarterial Infusion with the Antiglycolytic Agent 3-Bromopyruvate in the VX2 Model of Liver Tumor. Journal of Nuclear Medicine, 2011, 52, 225-230.	2.8	17
41	High-Resolution Ultrasound in Research of Mouse Orthotopic Glioma and Ultrasound-Guided Cell Implant. Advances in Molecular Imaging, 2011, 01, 24-32.	0.3	2
42	3-Bromopyruvate: A New Targeted Antiglycolytic Agent and a Promise for Cancer Therapy. Current Pharmaceutical Biotechnology, 2010, 11, 510-517.	0.9	110
43	The Pyruvic Acid Analog 3-Bromopyruvate Interferes With the Tetrazolium Reagent MTS in the Evaluation of Cytotoxicity. Assay and Drug Development Technologies, 2010, 8, 258-262.	0.6	21
44	Abstract 4462: Induction of apoptosis by 3-bromopyruvate involves endoplasmic reticulum (ER) stress and overcomes autophagy response in human hepatocellular carcinoma cell line Hep3B. , 2010, , .		0
45	3-Bromopyruvate induces endoplasmic reticulum stress, overcomes autophagy and causes apoptosis in human HCC cell lines. Anticancer Research, 2010, 30, 923-35.	0.5	44
46	A Pyruvic Acid Analog Primarily Targets GAPDH To Promote Cancer Cell Death. FASEB Journal, 2009, 23, 678.2.	0.2	0
47	Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is pyruvylated during 3-bromopyruvate mediated cancer cell death. Anticancer Research, 2009, 29, 4909-18.	0.5	107
48	Targeting of VX2 Rabbit Liver Tumor by Selective Delivery of 3-Bromopyruvate: A Biodistribution and Survival Study. Journal of Pharmacology and Experimental Therapeutics, 2008, 327, 32-37.	1.3	32
49	A critical role for the host mediator macrophage migration inhibitory factor in the pathogenesis of malarial anemia. Journal of Experimental Medicine, 2006, 203, 1185-1196.	4.2	128
50	Jun Blockade of Erythropoiesis: Role for Repression of GATA-1 by HERP2. Molecular and Cellular Biology, 2004, 24, 7779-7794.	1.1	61
51	Genetic analyses of the promoter region of interleukin-10 gene in different species of monkeys: implications for HIV/AIDS progression. Genes and Immunity, 2001, 2, 404-407.	2.2	1
52	High frequency of G to A transition mutation in the stromal cell derived factor-1 gene in India, a chemokine that blocks HIV-1 (X4) infection: multiple proteins bind to 3â€²-untranslated region of SDF-1 RNA. Genes and Immunity, 2001, 2, 408-410.	2.2	16
53	Ribozymes that cleave reovirus genome segment S1 also protect cells from pathogenesis caused by reovirus infection. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 4101-4106.	3.3	10
54	Genetic analyses of cis-acting sequences controlling expression of human immunodeficiency virus type 1 coreceptor-CCR5 gene in rabbits and CXCR4 gene in monkeys. Journal of Human Virology, 2001, 4, 188-94.	0.8	0

#	Article	IF	Citations
55	Novel HIV-1 co-receptor-CCR5 promoter mutations in simians: identification of two highly polymorphic regions with extensive deletions. Aids, 2000, 14, 2201.	1.0	3
56	?-Tocopherol in Artemia cysts: a report. Aquaculture International, 1996, 4, 377-378.	1.1	1